Hetal Gandhi, MD
Internal Medicine · Livonia, MINPI 1396754453
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 363 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 363 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$955
- Lilly USA, LLC$784
- Pfizer$647
- GSK$476
- Boehringer Ingelheim$404
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,41198%
- Education$1112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 56 | $1,145 |
| AbbVie(2 entities) | 63 | $955 |
| Lilly USA, LLC | 40 | $784 |
| Pfizer | 38 | $647 |
| GSK | 25 | $476 |
| Boehringer Ingelheim | 21 | $404 |
| Novo Nordisk | 22 | $369 |
| Amgen | 17 | $300 |
| Johnson & Johnson | 15 | $279 |
| Astellas Pharma US Inc | 9 | $224 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $110 |
| Endo Pharmaceuticals Inc. | 6 | $105 |
| Merck | 6 | $97 |
| Exact Sciences | 5 | $95 |
| Dexcom, Inc. | 5 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $60 |
| Teva Pharmaceuticals USA, Inc. | 4 | $57 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Cashflow Solutions, LLC | 4 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Circassia Inc. | 2 | $29 |
| Eisai Inc. | 2 | $26 |
| Abbott | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,522 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 99 | $86,225 |
| OzempicSemaglutide | 55 | $64,539 |
| EliquisApixaban | 49 | $55,670 |
| JardianceEmpagliflozin | 54 | $46,814 |
| MounjaroTirzepatide | 28 | $28,818 |
| JanuviaSitagliptin Phosphate | 23 | $26,586 |
| MyrbetriqMirabegron | 32 | $21,642 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $18,362 |
| XareltoRivaroxaban | 18 | $12,562 |
| TrintellixVortioxetine Hydrobromide | 22 | $12,123 |
| TradjentaLinagliptin | 14 | $9,046 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,130 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $2,702 |
| Atorvastatin Calcium | 162 | $2,081 |
| SynthroidLevothyroxine Sodium | 22 | $2,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,145 | $86,22599 claims |
| Novo NordiskOzempic | $369 | $64,53955 claims |
| Boehringer IngelheimJardiance, Tradjenta | $404 | $55,86068 claims |
| PfizerEliquis | $647 | $55,67049 claims |
| Lilly USA, LLCMounjaro | $784 | $28,81828 claims |
| MerckJanuvia | $97 | $26,58623 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $476 | $24,49239 claims |
| Astellas Pharma US IncMyrbetriq | $224 | $21,64232 claims |
| Johnson & JohnsonXarelto | $279 | $12,56218 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $110 | $12,12322 claims |
| AbbVieSynthroid | $955 | $2,01622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Livonia
- Steven KatzmanLivonia$715K
- Ala ShukerLivonia$21K
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- Mohamad HatahetWaterford$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.